Carlsmed Inc. Common Stock (CARL)
Stock · NASDAQ · Health Care
$13.41as of 10/16/2026
Price chart
Active signals
CARL Signal Track Record
How signals performed across all stocks →What CARL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 4 | +9.7% | 75% | September 18, 2026 |
| Bollinger Band Breakout | 4 | +0.8% | 50% | August 20, 2026 |
| Any 20-session window (baseline) | +8.1% | 65% |
Computed by MarketWall from daily closing prices since May 7, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CARL
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-buil…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 127
- Website
- carlsmed.com/
Fundamentals
- 1-day range
- $13.41$14.3
- Market cap
- $372.43M
- P/E (trailing)
- —
- P/E (forward)
- -9.72
- EPS (trailing)
- $-1.44
- Dividend yield
- —
- Beta
- 2.31
- Avg. volume
- 112.5K
How Carlsmed Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Carlsmed Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CARLCarlsmed Inc. Common Stock$13.41▼ 3.87%Market cap $372.43MP/E —$8.5$17.23
- SGHTSight Sciences Inc. Common Stock$8.28▼ 5.91%Market cap $385.77MP/E —$3.34$9.71
- CLPTClearPoint Neuro Inc. Common Stock$9.07▼ 5.91%Market cap $408.45MP/E —$8.27$28.1
- MOBIMobia Medical Inc. Common Stock$8.09▼ 2.65%Market cap $409.63MP/E —$8.16$15.29
- OFIXOrthofix Medical Inc. Common Stock (DE)$9.38▼ 2.19%Market cap $428.47MP/E —$8.5$16.99
- PROFProfound Medical Corp. Common Stock$6.01▼ 4.75%Market cap $288.52MP/E —$6.52$12.4
- DRTSWAlpha Tau Medical Ltd. Warrant$2.68▼ 10.37%Market cap $284.27MP/E —$0.2725$4.62
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CARL Carlsmed Inc. Common Stock | $372.43M | — | $13.41 | ▼ 3.87% | $8.5$17.23 |
| SGHT Sight Sciences Inc. Common Stock | $385.77M | — | $8.28 | ▼ 5.91% | $3.34$9.71 |
| CLPT ClearPoint Neuro Inc. Common Stock | $408.45M | — | $9.07 | ▼ 5.91% | $8.27$28.1 |
| MOBI Mobia Medical Inc. Common Stock | $409.63M | — | $8.09 | ▼ 2.65% | $8.16$15.29 |
| OFIX Orthofix Medical Inc. Common Stock (DE) | $428.47M | — | $9.38 | ▼ 2.19% | $8.5$16.99 |
| PROF Profound Medical Corp. Common Stock | $288.52M | — | $6.01 | ▼ 4.75% | $6.52$12.4 |
| DRTSW Alpha Tau Medical Ltd. Warrant | $284.27M | — | $2.68 | ▼ 10.37% | $0.2725$4.62 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Maintains Buy on Carlsmed, Raises Price Target to $24benzinga · 10/12/2026
- Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Carlsmed Appoints Tony Jarc as Chief Product and AI OfficerYahoo · 10/1/2026
- Carlsmed names new CFOYahoo · 9/29/2026
- Carlsmed Appoints Richard Heppenstall as Chief Financial OfficerYahoo · 9/28/2026
- BTIG Reiterates Buy on Carlsmed, Maintains $23 Price TargetBenzinga · 9/28/2026
- Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M EstBenzinga · 9/28/2026
- Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78MBenzinga · 9/28/2026
- Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen MedicalYahoo · 9/15/2026
Insider Activity
Insider Actions →- Bertolini Jeffrey · October 5, 2026 · Option Exercise747 @ $5.92
- Bertolini Jeffrey · October 5, 2026 · Sale747 @ $14.39
- Bertolini Jeffrey · September 30, 2026 · Option Exercise243 @ $2.23
- Bertolini Jeffrey · September 30, 2026 · Sale243 @ $13.99
- Bertolini Jeffrey · September 8, 2026 · Grant50.0K
- Sidow Kevin · June 3, 2026 · Grant13.7K
- Jonathan D. Root · June 3, 2026 · Grant13.7K
- Kevin C. Oboyle · June 3, 2026 · Grant13.7K
- YOUNG PHILIP M · June 3, 2026 · Grant13.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 5.20M
- Total value held
- $46.96M
- Institutional holders
- 62
- Unknown1.25M
- Unknown1.23M
- Unknown521.1K
- Unknown446.9K
- Unknown283.2K
- Unknown276.1K
- Unknown200.0K
- Unknown193.2K
- Unknown159.3K
- Unknown113.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed
Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.